Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum–taxane therapy: A phase II Austrian AGO study

Authors:
  • LAL. Angleitner-Boubenizek
    L. Angleitner-Boubenizek
  • ARA. Reinthaller
    A. Reinthaller
  • MDM. Deibl
    M. Deibl
  • AZA.G. Zeimet
    A.G. Zeimet
  • BVB. Volgger
    B. Volgger
  • ASA. Stempfl
    A. Stempfl
  • CMC. Marth
    C. Marth

Abstract
No abstract available

This publication has 6 references indexed in Scilit: